Work

Cord Blood Graft Engineering

Year: 2012

Type: article

Abstract: Once considered solely medical waste and routinely discarded as part of the afterbirth, umbilical cord blood (CB) is now commonly used as a source of hematopoietic stem cells (HSCs) for patients in need of HSC transplantation (HSCT) (or, as more commonly referred to, bone marrow transplantation) for the treatment of both malignant and nonmalignant disorders. In fact, more than 20,000 CB transplantations (CBTs) have been performed since the first one in 1988 [1], and this number increases annually as more recent data demonstrate outcomes for CBT recipients paralleling those for conventional HSCT recipients.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2012.10.015

Authors: Colleen Delaney, Catherine M. Bollard, Elizabeth J. Shpall

Institutions: University of Washington, Fred Hutch Cancer Center, Baylor College of Medicine, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650